We have located links that may give you full text access.
Journal Article
Review
Pharmacological strategies for preventing type 2 diabetes in patients with impaired glucose tolerance.
Drugs of Today 2013 August
Type 2 diabetes is an increasingly prevalent disease in the United States, and is associated with microvascular and macrovascular complications. Prediabetes, which is defined as impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT), increases the risk of development of type 2 diabetes. Lifestyle improvements, including weight loss and increased physical activity are effective in reducing the conversion of IGT to type 2 diabetes by 58%. However, lifestyle interventions alone may be difficult to maintain. Oral pharmacological agents used to treat type 2 diabetes that improve insulin sensitivity, preserve beta cell function and delay carbohydrate metabolism have been shown to prevent the progression of IGT to type 2 diabetes. The risk reduction of diabetes using metformin, pioglitazone, acarbose, valsartan and orlistat in clinical studies has ranged from 14 to 72%. Therefore, persons with IGT tolerance may benefit from pharmacological therapy to prevent the development of type 2 diabetes.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app